(redirected from NNRTI)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
See: deterrent
References in periodicals archive ?
Information regarding maternal ART and exposure of participants to prevention of mother-to-child transmission of HIV would have contributed to an understanding of participants with NNRTI mutations in whom there was no history of previous NNRTI-based ART regimens.
Although highly effective, NNRTI regimens have low genetic barrier.
The drugs belonging to the class of NNRTIs used were 600 mg efavirenz (EFZ) and 200mg nevirapine (NVP).
In the event of stopping ART due to NNRTI toxicity the NRTI backbone should be continued for a week after the stop date in order to cover the NNRTI tail.
This does not apply to the new second-generation NNRTI (not yet available in South Africa) etravirine, which needs a few NNRTI mutations for high-level resistance.
Money noted, "but more clinical research is needed, especially to evaluate the differences between NNRTI and PI regimens, in order to make the best treatment decisions.
This combinations seems to be very potent in patients who have never taken NNRTIs before, but who have taken drugs from the protease inhibitor class.
Sustiva product labeling also states that resistant virus emerges rapidly when NNRTIs are administered as monotherapy.
Highly active antiretroviral therapy regimens (N=64) Patients, n Stavudine (NRTI)/lamivudine (NRTI)/efavirenz (NNRTI) 56 Stavudine (NRTI)/lamivudine (NRTI)/nevirapine (NNRTI) 4 Zidovudine (NRTI)/lamivudine (NRTI)/efavirenz (NNRTI) 1 Stavudine (NRTI)/nevirapine (NNRTI)/didanosine (NRTI) 1 Lamivudine (NRTI)/efavirenz (NNRTI)/tenofovir (PI) 1 Lamivudine (NRTI)/didanosine (NRTI)/nevirapine (NNRTI) 1 NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor.
3) However, when analyzing NNRTI class, the majority of the studies showed an increase in drug resistance.
1) Drug-drug interactions were more frequent among people taking a PI or an NNRTI than among people taking Isentress.
Of 153 HIV-1-infected patients, 74 were receiving highly active antiretroviral therapy: a nucleoside reverse transcriptase inhibitor (NRTI) and a protease inhibitor (PI) (n = 35 patients); an integrase inhibitor (INI), an NRTI, and a PI (n = 7); a nonnucleoside-reverse transcriptase inhibitor and an NRTI (n = 26); an INI and an NRTI (n = 2); an INI and an NNRTI (n = 2); a chemokine receptor type 5 antagonist, an NRTI, and a PI (n = 1); and a chemokine receptor type 5 antagonist, an INI, and a nonnucleoside-reverse transcriptase inhibitor (n = 1).